AnaptysBio - Home
About
Overview
Strategy
Management
Board of Directors
Therapeutic Advisory Board
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
ANB020
ANB019
Checkpoint Agonists
Partnerships
Investors / News
Overview
News
Events
Goverance
Stock Information
Analyst Coverage
SEC Filings
FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Contact
Toggle
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
May 29, 2018
AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress
AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress
May 8, 2018
AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates
AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates
About
Technology
Pipeline
Investors
Careers
